Trademark: 97560320
Word
ULIBDI
Status
Pending
Status Code
688
Status Date
Tuesday, December 5, 2023
Serial Number
97560320
Mark Type
4000
Filing Date
Tuesday, August 23, 2022
Published for Opposition
Tuesday, October 10, 2023

Trademark Owner History
Prometheus Biosciences, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations used for the treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer
1 Diagnostic preparations for clinical or medical laboratory use; diagnostic reagents for clinical or medical laboratory use
44 Health care services, namely, disease management programs; medical services, namely, providing medical information to health care providers, managed care providers and patients via computer networks; providing health information in the field of gastrointestinal diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; providing information relating to medical diagnostic testing; providing information relating to medical treatment recommendation; medical consultation; providing a website featuring information about medical services for the diagnosis, prevention, and treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer; medical diagnostic testing provided by medical laboratories; medical analysis services in the nature of laboratory testing for disease management and patient diagnosis and patient selection for the diagnosis and treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, provided by medical laboratories; medical analysis services relating to the treatment of patients in the nature of laboratory testing for the purpose of immune modulation and management of side effects associated with renal disorders and cancer, provided by medical laboratories
42 Medical laboratory services, namely, laboratory testing for scientific research purposes and medical research services; medical laboratory services, namely, laboratory testing for scientific research purposes in the field of disease management and gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; medical laboratory services, namely, laboratory testing for scientific research of immune modulation and management of side effects associated with renal disorders and cancer pathology; medical laboratory services, namely, laboratory testing for scientific research of patient disease diagnoses and for patient selection for clinical trials

Trademark Events
Dec 5, 2023
Noa E-Mailed - Sou Required From Applicant
Oct 10, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 10, 2023
Published For Opposition
Sep 20, 2023
Notification Of Notice Of Publication E-Mailed
Sep 6, 2023
Approved For Pub - Principal Register
Sep 6, 2023
Examiner's Amendment Entered
Sep 6, 2023
Notification Of Examiners Amendment E-Mailed
Sep 6, 2023
Examiners Amendment E-Mailed
Sep 6, 2023
Examiners Amendment -Written
Aug 23, 2023
Teas/Email Correspondence Entered
Aug 22, 2023
Correspondence Received In Law Office
Aug 22, 2023
Teas Response To Office Action Received
Jun 13, 2023
Notification Of Non-Final Action E-Mailed
Jun 13, 2023
Non-Final Action E-Mailed
Jun 13, 2023
Non-Final Action Written
Jun 9, 2023
Assigned To Examiner
Apr 3, 2023
Teas Change Of Correspondence Received
Apr 3, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 3, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Sep 12, 2022
New Application Office Supplied Data Entered
Aug 26, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24